Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.31 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667232 | 0.89 | DRD1 (0.31) | DRD1GABBR2GABBR1KIF11 | |
| SCHEMBL667936 | 0.89 | DRD1 (0.37) | DRD1 | |
| SCHEMBL15685860 | 0.88 | DRD1 (0.50) | DRD1 | |
| SCHEMBL668454 | 0.86 | ALDH1A1 (0.39) | DRD1LMNA | |
| SCHEMBL666909 | 0.79 | DRD1 (0.65) | DRD1 | |
| SCHEMBL708320 | 0.77 | DRD1 (0.61) | DRD1GABBR2GABBR1 | |
| SCHEMBL15849058 | 0.76 | ALDH1A1 (0.34) | GABBR2GABBR1NPC1RAB9ALMNA | |
| SCHEMBL1537187 | 0.75 | DRD1 (0.47) | DRD1GABBR2GABBR1 | |
| SCHEMBL21111854 | 0.74 | DRD1 (0.55) | DRD1 | |
| SCHEMBL29501658 | 0.74 | DRD1 (0.55) | DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912346-B2 | Palladium phosphine complexes for the telomerization of butadiene | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-12-16 | — | — | US | claimed |
| EP-2431375-B1 | PALLADIUM PHOSPHINE COMPLEXES FOR THE TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-05-01 | — | — | EP | claimed |
| EP-2431375-A2 | PALLADIUM PHOSPHINE COMPLEXES FOR THE TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (US) | 2012-03-21 | — | — | EP | claimed |
| US-20120046475-A1 | PALLADIUM PHOSPHINE COMPLEXES FOR THE TELEOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-02-23 | — | — | US | claimed |
| US-8912346-B2 | Palladium phosphine complexes for the telomerization of butadiene | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2431375-B1 | PALLADIUM PHOSPHINE COMPLEXES FOR THE TELOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2431375-A2 | PALLADIUM PHOSPHINE COMPLEXES FOR THE TELOMERIZATION OF BUTADIENE | Dow Global Technologies LLC (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120046475-A1 | PALLADIUM PHOSPHINE COMPLEXES FOR THE TELEOMERIZATION OF BUTADIENE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046475-A1 | PALLADIUM PHOSPHINE COMPLEXES FOR THE TELEOMERIZATION OF BUTADIENE | TTI1, TTI2, PAXBP1 | DRD1 258/4885GABBR2 2233/4885GABBR1 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.